Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-21-154061
Filing Date
2021-12-29
Accepted
2021-12-29 06:14:46
Documents
1

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2136487d1_defa14a.htm DEFA14A 14232
  Complete submission text file 0001104659-21-154061.txt   15253
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-13341 | Film No.: 211526100
SIC: 2836 Biological Products, (No Diagnostic Substances)